Titre : Personnes se prêtant à la recherche

Personnes se prêtant à la recherche : Questions médicales fréquentes

Termes MeSH sélectionnés :

Double-Blind Method
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Personnes se prêtant à la recherche : Questions médicales les plus fréquentes", "headline": "Personnes se prêtant à la recherche : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Personnes se prêtant à la recherche : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-25", "dateModified": "2025-04-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Personnes se prêtant à la recherche" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Personnes", "url": "https://questionsmedicales.fr/mesh/D009272", "about": { "@type": "MedicalCondition", "name": "Personnes", "code": { "@type": "MedicalCode", "code": "D009272", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "M01" } } }, "about": { "@type": "MedicalCondition", "name": "Personnes se prêtant à la recherche", "alternateName": "Research Subjects", "code": { "@type": "MedicalCode", "code": "D035842", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Stephanie Morain", "url": "https://questionsmedicales.fr/author/Stephanie%20Morain", "affiliation": { "@type": "Organization", "name": "Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX." } }, { "@type": "Person", "name": "Kemal Hakan Gülkesen", "url": "https://questionsmedicales.fr/author/Kemal%20Hakan%20G%C3%BClkesen", "affiliation": { "@type": "Organization", "name": "Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, Braunschweig, Germany." } }, { "@type": "Person", "name": "Reinhold Haux", "url": "https://questionsmedicales.fr/author/Reinhold%20Haux", "affiliation": { "@type": "Organization", "name": "Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, Braunschweig, Germany." } }, { "@type": "Person", "name": "Sungwoo Um", "url": "https://questionsmedicales.fr/author/Sungwoo%20Um", "affiliation": { "@type": "Organization", "name": "Department of Ethics Education, Seoul National University, 1, Gwanak-Ro, 11-411, Gwanak-Gu, 08826, South Korea. sungwooum@snu.ac.kr." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Individualized Homeopathic Medicines in the Treatment of Psoriasis Vulgaris: Double-Blind, Randomized, Placebo-Controlled Trial.", "datePublished": "2023-06-01", "url": "https://questionsmedicales.fr/article/37263249", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1159/000530180" } }, { "@type": "ScholarlyArticle", "name": "Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial.", "datePublished": "2022-09-22", "url": "https://questionsmedicales.fr/article/36136861", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/MPG.0000000000003622" } }, { "@type": "ScholarlyArticle", "name": "Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.", "datePublished": "2022-07-28", "url": "https://questionsmedicales.fr/article/35896988", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s10194-022-01458-0" } }, { "@type": "ScholarlyArticle", "name": "The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.", "datePublished": "2024-09-20", "url": "https://questionsmedicales.fr/article/39301594", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1192/j.eurpsy.2024.1768" } }, { "@type": "ScholarlyArticle", "name": "A Dietary Supplement in the Management of Patients with Lumbar Osteochondrosis: A Randomized, Double-Blinded, Placebo-Controlled Study.", "datePublished": "2024-08-14", "url": "https://questionsmedicales.fr/article/39203831", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/nu16162695" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Personnes", "item": "https://questionsmedicales.fr/mesh/D009272" }, { "@type": "ListItem", "position": 3, "name": "Personnes se prêtant à la recherche", "item": "https://questionsmedicales.fr/mesh/D035842" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Personnes se prêtant à la recherche - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Personnes se prêtant à la recherche", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Personnes se prêtant à la recherche", "description": "Comment sont sélectionnés les sujets de recherche ?\nQuels tests sont effectués sur les sujets ?\nLes sujets sont-ils informés des risques ?\nComment évaluer la santé des sujets ?\nQuelles données sont collectées sur les sujets ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Personnes se prêtant à la recherche", "description": "Les sujets ressentent-ils des effets secondaires ?\nComment les symptômes sont-ils suivis ?\nLes symptômes varient-ils selon les traitements ?\nLes sujets peuvent-ils signaler des symptômes ?\nY a-t-il un suivi des symptômes après l'étude ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Personnes se prêtant à la recherche", "description": "Les sujets reçoivent-ils des conseils préventifs ?\nY a-t-il des vaccinations pour les sujets ?\nComment prévenir les effets indésirables ?\nLes sujets sont-ils formés à la prévention ?\nY a-t-il des recommandations diététiques ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Personnes se prêtant à la recherche", "description": "Quels types de traitements sont testés ?\nLes traitements sont-ils randomisés ?\nComment les traitements sont-ils administrés ?\nLes sujets reçoivent-ils un placebo ?\nComment évaluer l'efficacité des traitements ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Personnes se prêtant à la recherche", "description": "Quelles complications peuvent survenir ?\nComment sont gérées les complications ?\nLes sujets sont-ils suivis après des complications ?\nLes complications sont-elles documentées ?\nY a-t-il des critères pour signaler des complications ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Personnes se prêtant à la recherche", "description": "Quels facteurs de risque sont évalués ?\nLes sujets sont-ils informés des facteurs de risque ?\nComment les facteurs de risque influencent-ils l'étude ?\nLes facteurs de risque sont-ils mesurés ?\nY a-t-il des interventions pour réduire les risques ?", "url": "https://questionsmedicales.fr/mesh/D035842?mesh_terms=Double-Blind+Method&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment sont sélectionnés les sujets de recherche ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les sujets sont choisis selon des critères spécifiques liés à l'étude." } }, { "@type": "Question", "name": "Quels tests sont effectués sur les sujets ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests cliniques, biologiques et d'imagerie peuvent être réalisés." } }, { "@type": "Question", "name": "Les sujets sont-ils informés des risques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'information sur les risques est essentielle avant le consentement." } }, { "@type": "Question", "name": "Comment évaluer la santé des sujets ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des évaluations médicales régulières sont effectuées tout au long de l'étude." } }, { "@type": "Question", "name": "Quelles données sont collectées sur les sujets ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des données démographiques, cliniques et de réponse au traitement sont collectées." } }, { "@type": "Question", "name": "Les sujets ressentent-ils des effets secondaires ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets secondaires peuvent survenir et doivent être signalés." } }, { "@type": "Question", "name": "Comment les symptômes sont-ils suivis ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes sont suivis par des questionnaires et des évaluations cliniques." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon les traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent varier en fonction du traitement administré." } }, { "@type": "Question", "name": "Les sujets peuvent-ils signaler des symptômes ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sujets sont encouragés à signaler tout symptôme nouveau ou aggravé." } }, { "@type": "Question", "name": "Y a-t-il un suivi des symptômes après l'étude ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi peut être proposé pour évaluer les effets à long terme." } }, { "@type": "Question", "name": "Les sujets reçoivent-ils des conseils préventifs ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des conseils sur la santé et la prévention des maladies peuvent être fournis." } }, { "@type": "Question", "name": "Y a-t-il des vaccinations pour les sujets ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations peuvent être administrées selon les protocoles de l'étude." } }, { "@type": "Question", "name": "Comment prévenir les effets indésirables ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives et un suivi régulier aident à minimiser les effets indésirables." } }, { "@type": "Question", "name": "Les sujets sont-ils formés à la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une formation sur la prévention des maladies peut être incluse dans l'étude." } }, { "@type": "Question", "name": "Y a-t-il des recommandations diététiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des recommandations diététiques peuvent être fournies pour améliorer la santé des sujets." } }, { "@type": "Question", "name": "Quels types de traitements sont testés ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments, des thérapies physiques et des interventions chirurgicales peuvent être testés." } }, { "@type": "Question", "name": "Les traitements sont-ils randomisés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, de nombreuses études utilisent des méthodes randomisées pour réduire les biais." } }, { "@type": "Question", "name": "Comment les traitements sont-ils administrés ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent être administrés par voie orale, intraveineuse ou topique." } }, { "@type": "Question", "name": "Les sujets reçoivent-ils un placebo ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Dans certaines études, un groupe de sujets peut recevoir un placebo pour comparaison." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des mesures cliniques et des questionnaires standardisés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications liées aux traitements ou à la maladie peuvent survenir." } }, { "@type": "Question", "name": "Comment sont gérées les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont gérées par des interventions médicales appropriées." } }, { "@type": "Question", "name": "Les sujets sont-ils suivis après des complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi est souvent prévu pour évaluer la récupération des sujets." } }, { "@type": "Question", "name": "Les complications sont-elles documentées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, toutes les complications doivent être soigneusement documentées dans l'étude." } }, { "@type": "Question", "name": "Y a-t-il des critères pour signaler des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des critères spécifiques sont établis pour le signalement des complications." } }, { "@type": "Question", "name": "Quels facteurs de risque sont évalués ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le sexe, et les antécédents médicaux sont évalués." } }, { "@type": "Question", "name": "Les sujets sont-ils informés des facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les sujets reçoivent des informations sur les facteurs de risque associés à l'étude." } }, { "@type": "Question", "name": "Comment les facteurs de risque influencent-ils l'étude ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent influencer les résultats et la généralisation des conclusions de l'étude." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils mesurés ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des questionnaires et des évaluations médicales mesurent les facteurs de risque." } }, { "@type": "Question", "name": "Y a-t-il des interventions pour réduire les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des interventions peuvent être proposées pour réduire les facteurs de risque identifiés." } } ] } ] }

Sources (10000 au total)

Individualized Homeopathic Medicines in the Treatment of Psoriasis Vulgaris: Double-Blind, Randomized, Placebo-Controlled Trial.

Psoriasis is a chronic inflammatory skin disorder, affecting the trunk and extensor surfaces of the limbs and scalp predominantly. Worldwide prevalence ranges between 0.1 and 11.4%, and in India betwe... This 6-month, double-blind, randomized trial was conducted on 51 patients suffering from psoriasis at the National Institute of Homoeopathy, India. Patients were randomized to receive either individua... Although intragroup changes were significant in both groups in the outcome measures, improvements were significantly higher in the IHMs group than in placebos in PASI scores after 6 months of interven... IHMs exhibited better results than placebos in the treatment of psoriasis. Further research is warranted.... <title>Einleitung</title>Psoriasis ist eine chronisch entzündliche Hauterkrankung, die vor allem den Körperstamm und die Streckseiten der Extremitäten sowie die Kopfhaut betrifft. Die weltweite Präval...

Efficacy of Oral Psyllium in Pediatric Irritable Bowel Syndrome: A Double-Blind Randomized Control Trial.

Pediatric irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with variable response to various therapeutic agents. Psyllium has been proven to be effective in adults; howe... In this double-blind randomized controlled trial, 43 children were assigned to psyllium arm (Group A) and 38 into placebo arm (Group B). Severity is assessed at baseline and after 4 weeks of treatment... Mean ages (±SD; in years) of Groups A and B were 9.87 (2.7) and 9.82 (3.17), respectively, with median duration of illness of 12 months. At baseline, type, severity, and parameters (IBS-SSS) of IBS we... Psyllium husk is effective for the therapy of pediatric IBS when compared with placebo in short term....

Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.

Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated efficacy and good tolerability in patients with episodic migraine in previous phase 3 trials.... This phase 3 study was conducted at 40 centers in China (n = 26), India (n = 10), and Russia (n = 4). Eligible adult patients with episodic migraine were randomized in a 1:1 ratio to receive monthly g... In total, 520 patients were randomized and received at least one dose of galcanezumab (N = 261) or placebo (N = 259). The least squares (LS) mean reduction from baseline in monthly MHDs over 3 months ... Galcanezumab 120 mg once monthly was effective and well tolerated in patients with episodic migraine from China, India, and Russia.... ClinicalTrials.gov Identifier NCT03963232 (PERSIST), registered May 24, 2019....

The minimal important difference in obsessive-compulsive disorder: An analysis of double-blind SSRI trials in adults.

The change in symptoms necessary to be clinically relevant in obsessive-compulsive disorder (OCD) is currently unknown. In this study, we aimed to create an empirically validated threshold for clinica... We analyzed individual participant data from short-term, double-blind, placebo-controlled registration trials of selective serotonin reuptake inhibitors in adult OCD patients. Data were collected from... We included 7 trials with a total of 1216 patients. The CGI-scores and YBOCS were moderately to highly correlated. The MID corresponded to 4.9 YBOCS points (95% CI 4.4-5.4) for the full sample, or a 2... By linking the YBOCS to the CGI-I, this is the first study to propose an MID in OCD trials. Having a clearly defined MID can guide future clinical research and help interpretation of efficacy of exist...

The clinical effect of benesco™ on reflux symptoms: A double-blind randomized placebo-controlled trial.

Gastroesophageal reflux disease (GERD) is one of the most prevalent gastrointestinal diseases in the western world. Lifestyle modifications and proton pump inhibitors (PPIs) form the basis of the mana... We performed a double-blind randomized placebo-controlled trial in participants with reflux symptoms. Participants were assigned randomly (1:1) to receive 6 weeks of benesco™ (three times daily one lo... One hundred participants were randomized. Treatment success was seen in 18 (39%) of 46 participants in the intervention group versus 21 (47%) of 45 in the placebo group (p = 0.468). In the interventio... In our trial benesco™ showed no significant benefit over placebo at group level....

Turpentine Ointment in Bacterial Skin Infections: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial.

Turpentine-containing substances are considered effective in treating cutaneous bacterial infections, but reliable clinical data are scant.... We investigated the efficacy and safety of an ointment containing larch turpentine (from Larix decidua), eucalyptus oil (from Eucalyptus globulus), and turpentine oil (from Pinus pinaster) in outpatie... 116 outpatients with skin abscesses used verum or placebo for 10 days. Sum score of the patient's discomforts, changes in abscess size, rate of therapeutic success, and complete healing served as outc... Fifty-four patients were treated with verum and 56 with placebo. According to the patient's discomfort sum score, patients in the verum group showed a better improvement compared to the placebo group ... The ointment studied is an effective and safe option for the treatment of bacterial skin diseases....

Individualized Homeopathic Medicines in Treatment of Hyperuricemia: Evaluation by Double-Blind, Randomized, Placebo-Controlled Trial.

Hyperuricemia (HU) is a major health issue in India and across the globe. It increases the disease burden and hampers quality of life. This study was aimed at exploring the effects of individualized h... This double-blind, randomized, placebo-controlled trial was conducted on 60 patients suffering from HU in the outpatient department of D. N. De Homoeopathic Medical College and Hospital, Kolkata. Each... The intention-to-treat sample (... IHMs showed significantly better results than placebos in reducing SUA levels and improving quality of life in patients suffering from HU.... CTRI/2019/10/021503; UTN: U1111-1241-1431....

Individualized Homeopathic Medicines in the Treatment of Tinea Corporis: Double-Blind, Randomized, Placebo-Controlled Trial.

Tinea corporis (TC; ringworm or dermatophytosis) is a superficial skin infection caused by... A double-blind, randomized, placebo-controlled, two parallel arms trial was conducted on 62 individuals suffering from TC at the National Institute of Homoeopathy, India. Participants were randomized ... The primary outcome revealed no improvement in either of the groups (... Results were negative on the primary outcome; however, secondary outcomes included some statistically significant results favoring IHMs against placebo after 3 months.... CTRI/2019/11/021999; UTN: U1111-1242-0070....